𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Second-line and subsequent therapy for ovarian carcinoma

✍ Scribed by Prema P. Peethambaram; Harry J. Long

Book ID
107546185
Publisher
Current Science Inc.
Year
2002
Tongue
English
Weight
276 KB
Volume
4
Category
Article
ISSN
1523-3790

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Subsequent primary malignancies after en
Subsequent primary malignancies after endometrial carcinoma and ovarian carcinoma
✍ Kari Hemminki; Lauri Aaltonen; Xinjun Li πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 93 KB

## Abstract ## BACKGROUND Population‐based data on subsequent neoplasms after women are diagnosed with endometrial and ovarian carcinomas are limited, particularly regarding specific histologic tumor types. ## METHODS The nationwide Swedish Family‐Cancer Database of 10.2 million individuals, whi

Is paclitaxel and cisplatin a cost-effec
Is paclitaxel and cisplatin a cost-effective first-line therapy for advanced ovarian carcinoma?
✍ Allan Covens; Sylvain Boucher; Kathie Roche; Moira Macdonald; Daniel Pettitt; Br πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 567 KB

## BACKGROUND. Paclitaxel and cisplatin use for the treatment of advanced ovarian carcinoma (AOC) has been shown to increase median sunrival duration. An evaluation was performed on the economic consequences of treating AOC patients with combined paclitaxel and cisplatin chemotherapy compared with